Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
06/04/18 GEM020 3rd generation immunotherapy targeting little gastrin Gastro-intestinal cancer (Pancreatic) SC Preclinical -Applied 3rd generation immunotherapy technology to little gastrin.
-In-vivo POC has been validated in non-human primates.
Contact
06/04/18 GEM019 3rd generation immunotherapy targeting HER2 HER2 overexpressing cancer (Breast) SC Preclinical -Applied 3rd generation immunotherapy technology to HER2.
-Superior efficacy to trastuzumab and pertuzumab.
-In-vivo PoC has been validated in non-human primates.
Contact
06/04/18 GEM018 3rd generation immunotherapy technology Cancer SC Discovery -Unique technology that triggers B and T cells simultaneously while activating all possible natural tumor killing mechanisms available to the immune-system.
-Tumor-directed specific activation reduces side effects to the minimum.
-Applicable on a target basis.
Contact
05/31/18 GEM009 BET inhibitor Cancer, Rheumatoid Arthritis Oral Preclinical More potent activities and lower risk of cardiovascular toxicities than competitors Contact
04/10/18 GEM008 Selective cMET inhibitor NSCLC and HCC etc. Oral Phase 2 Effective on exon 14 skipping xenograft Contact
03/26/18 GEM007 Vaccine Anthrax Oral Discovery~ Preclinical A cost-effective and safer vaccine that would produce immunity to anthrax with fewer doses Contact
03/26/18 GEM006 Bacterial NADH production inhibitor Bacterial infection Discovery~ Preclinical Inhibits synthesis of NADH in bacteria, but not in humans and expected to be used for treatment of multi-drug resistant pathogens Contact
03/26/18 GEM005 Androgen receptor down-regulator Prostate cancer Discovery~ Preclinical Decreases androgen receptor expression or function as well as androgen synthesis Contact
03/26/18 GEM004 Actin polymerization blocker Cancer Discovery Blocks actin polymerization by targeting an actin-associated protein and inhibits infiltration and metastasis Contact
12/28/17 GEM003 Selective glucocorticoid receptor agonist RA/OA Local Preclinical Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation) Contact